 |
|
Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment
Anja H. Simonsen, MSc;
James McGuire, PhD;
Oskar Hansson, MD, PhD;
Henrik Zetterberg, MD, PhD;
Vladimir N. Podust, PhD;
Huw A. Davies, PhD;
Gunhild Waldemar, MD, PhD;
Lennart Minthon, MD, PhD;
Kaj Blennow, MD, PhD
Arch Neurol. 2007;64(3):366-370.
Objective To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides able to differentiate between patients with stable mild cognitive impairment (MCI) and those who will progress to Alzheimer disease (AD).
Design Baseline cerebrospinal fluid samples from patients with MCI and healthy controls were profiled using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Setting Memory disorder clinic.
Participants Patients with MCI (n = 113), of whom 56 were cognitively stable and 57 progressed to AD with dementia during a 4- to 6-year follow-up, as well as 28 healthy controls who were followed up for 3 years.
Main Outcome Measure During follow-up, 57 patients progressed to AD and 56 patients had stable MCI. Cerebrospinal fluid from these 2 groups of patients was compared using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Results We identified a panel of 17 potential biomarkers that could distinguish between patients with stable MCI and patients with MCI who progressed to AD. We have positively identified and characterized 5 of the potential biomarkers.
Conclusions Proteomic profiling of cerebrospinal fluid provided a novel panel of 17 potential biomarkers for prediction of MCI progression to AD. The 5 identified biomarkers are relevant to the pathogenesis of AD and could help gain an understanding of the molecular pathways in which they may function.
Author Affiliations: Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc (Ms Simonsen and Drs McGuire and Davies) and Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital (Ms Simonsen and Dr Waldemar), Copenhagen, Denmark; Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden (Drs Hansson and Minthon); Department of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden (Drs Zetterberg and Blennow); and Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc, Fremont, Calif (Dr Podust).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Serum cystatin C and the risk of Alzheimer disease in elderly men
Sundelof et al.
Neurology 2008;71:1072-1079.
ABSTRACT
| FULL TEXT
Mass spectrometry is only one piece of the puzzle in clinical proteomics
McGuire et al.
Brief Funct Genomic Proteomic 2008;0:eln005v1-eln005.
ABSTRACT
| FULL TEXT
BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics
Seabrook et al.
Mol. Interv. 2007;7:261-270.
ABSTRACT
| FULL TEXT
|
